Trial Profile
Phase I Study With SYL040012. Tolerance and Effect on Intraocular Pressure
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 May 2014
Price :
$35
*
At a glance
- Drugs Bamosiran (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions
- Sponsors Sylentis
- 07 May 2014 New trial record